ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|September 11, 2019
GE Healthcare to Partner with NIBRT for Biopharma Education Program
Author(s)BioPharm International Editors
The companies plan to create a new curriculum focusing on single-use applications training, cell therapy technology, process efficiency strategies, process development methodologies, and chromatography proficiency.
Advertisement
GE Healthcare (GEHC) announced on Sept. 11, 2019 that it is teaming up with the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, to deliver educational programming on biopharmaceutical and cell therapy development and manufacturing.
The companies plan to share GEHC’s Fast Trak training and education curriculum and will co-develop a new curriculum to help the global biomanufacturing industry meet the needs of changing technologies and modalities,. The new curriculum will feature single-use applications training, cell-therapy technology, process efficiency strategies, process development methodologies, and chromatography proficiency.
“At NIBRT, we pride ourselves on our best-in-class education and training programs that support the thriving biopharmaceutical industry. By working with GEHC we will be able to leverage their biomanufacturing expertise to create exciting new programs designed to meet the global demand for talent,” said Killian O’Driscoll, director of projects, NIBRT, in the press release.
Courses will be available at the Jefferson Institute of Bioprocessing in Philadelphia, PA, the NIBRT facility in Dublin, and at GEHC Fast Trak locations in the United States, South Korea, Sweden, India, China, Turkey, Japan, and Singapore.
Source:
Advertisement
Related to this article
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5